Wegovy (semaglutide) and Mounjaro (tirzepatide) are brand-name injections. Wegovy is prescribed for weight loss and to lower cardiovascular risks. Mounjaro is approved for type 2 diabetes ...

After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...

A major new study has found that women over 55 are leading the way in weight loss –outperforming younger users of Wegovy and Mounjaro by a significant margin. The research, conducted by Voy ...

The latest weight-loss drugs including Ozempic, Wegovy, Mounjaro, and Zepbound have list prices ranging from $900 to $1,500 for a one-month supply. David Ricks, the CEO of Mounjaro and Zepbound ...

"Demand for the medications Mounjaro, Zepbound, Ozempic, and Wegovy (GLP-1 drugs) has skyrocketed, but supply shortages and high costs have created opportunities for wrongdoers to cash in and ...

Medications like Mounjaro and Wegovy have been hailed as "game changers" for tackling obesity.

MEDVi is a telehealth platform designed to provide personalized weight loss solutions through FDA-approved GLP-1 medications such as Semaglutide (Ozempic®, Wegovy®) and Tirzepatide (Mounjaro®).

The Food and Drug Administration on Friday said the shortage of Novo Nordisk's weight-loss and diabetes drugs Wegovy and Ozempic ... sold under the brand names Mounjaro and Zepbound, was no ...

Demand for weight loss jabs continues to surge and has been spurred on by the NHS offering Wegovy to patients and will start offering Mounjaro in March 2025. They have also become increasingly popular ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer ... that shortages of tirzepatide injections Zepbound and Mounjaro from competitor Eli Lilly had also ended.

Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...